Unmodified autologous stem cells at point of care for chronic myocardial infarction.
Adipose tissue-derived regenerative cells
Chronic myocardial infarction
Heart failure
Point of care cell therapy
Stem cells
Translational medicine
Journal
World journal of stem cells
ISSN: 1948-0210
Titre abrégé: World J Stem Cells
Pays: United States
ID NLM: 101535826
Informations de publication
Date de publication:
26 Oct 2019
26 Oct 2019
Historique:
received:
18
02
2019
revised:
05
06
2019
accepted:
26
08
2019
entrez:
7
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
ppublish
Résumé
Numerous studies investigated cell-based therapies for myocardial infarction (MI). The conflicting results of these studies have established the need for developing innovative approaches for applying cell-based therapy for MI. Experimental studies on animal models demonstrated the potential of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) for treating acute MI. In contrast, studies on the treatment of chronic MI (CMI; > 4 wk post-MI) with UA-ADRCs have not been published so far. Among several methods for delivering cells to the myocardium, retrograde delivery into a temporarily blocked coronary vein has recently been demonstrated as an effective option. To test the hypothesis that in experimentally-induced chronic myocardial infarction (CMI; > 4 wk post-MI) in pigs, retrograde delivery of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) into a temporarily blocked coronary vein improves cardiac function and structure. The left anterior descending (LAD) coronary artery of pigs was blocked for 180 min at time point T0. Then, either 18 × 10 Unlike the delivery of saline, delivery of UA-ADRCs demonstrated statistically significant improvements in cardiac function and structure at T2 compared to T1 (all values given as mean ± SE): Increased mean LVEF (UA-ADRCs group: 34.3% ± 2.9% at T1 Retrograde cell delivery of UA-ADRCs in a porcine model for the study of CMI significantly improved myocardial function, increased myocardial mass and reduced the formation of scar tissue.
Sections du résumé
BACKGROUND
BACKGROUND
Numerous studies investigated cell-based therapies for myocardial infarction (MI). The conflicting results of these studies have established the need for developing innovative approaches for applying cell-based therapy for MI. Experimental studies on animal models demonstrated the potential of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) for treating acute MI. In contrast, studies on the treatment of chronic MI (CMI; > 4 wk post-MI) with UA-ADRCs have not been published so far. Among several methods for delivering cells to the myocardium, retrograde delivery into a temporarily blocked coronary vein has recently been demonstrated as an effective option.
AIM
OBJECTIVE
To test the hypothesis that in experimentally-induced chronic myocardial infarction (CMI; > 4 wk post-MI) in pigs, retrograde delivery of fresh, uncultured, unmodified, autologous adipose-derived regenerative cells (UA-ADRCs) into a temporarily blocked coronary vein improves cardiac function and structure.
METHODS
METHODS
The left anterior descending (LAD) coronary artery of pigs was blocked for 180 min at time point T0. Then, either 18 × 10
RESULTS
RESULTS
Unlike the delivery of saline, delivery of UA-ADRCs demonstrated statistically significant improvements in cardiac function and structure at T2 compared to T1 (all values given as mean ± SE): Increased mean LVEF (UA-ADRCs group: 34.3% ± 2.9% at T1
CONCLUSION
CONCLUSIONS
Retrograde cell delivery of UA-ADRCs in a porcine model for the study of CMI significantly improved myocardial function, increased myocardial mass and reduced the formation of scar tissue.
Identifiants
pubmed: 31692971
doi: 10.4252/wjsc.v11.i10.831
pmc: PMC6828597
doi:
Types de publication
Journal Article
Langues
eng
Pagination
831-858Informations de copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Schmitz C has served as consultant of SciCoTec (Grünwald, Germany), the principal shareholder of InGeneron, Inc. (Houston, TX, United States). Alt EU is Chairman of the Board of Isar Klinikum and of InGeneron, Inc.
Références
Cell Signal. 2009 Dec;21(12):1717-26
pubmed: 19540337
Mol Imaging Biol. 2011 Aug;13(4):633-45
pubmed: 20730500
Nat Rev Cardiol. 2018 Nov;15(11):659-671
pubmed: 29743563
Cell. 2015 Jun 18;161(7):1566-75
pubmed: 26073943
Int J Cardiovasc Imaging. 2002 Feb;18(1):539-42
pubmed: 12135124
Eur J Pharm Biopharm. 2013 May;84(1):29-39
pubmed: 23266493
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Trends Biotechnol. 2006 Apr;24(4):150-4
pubmed: 16488036
JACC Cardiovasc Imaging. 2011 Feb;4(2):150-6
pubmed: 21329899
Eur Heart J. 2016 Jun 14;37(23):1789-98
pubmed: 27055812
Cardiovasc Res. 1986 Dec;20(12):907-17
pubmed: 3802126
Rev Esp Cardiol (Engl Ed). 2015 Jul;68(7):599-611
pubmed: 26028258
Eur Heart J. 2007 Nov;28(21):2667-77
pubmed: 17933755
Stem Cells. 2018 Apr;36(4):482-500
pubmed: 29330880
Eur Heart J. 2010 Feb;31(4):489-501
pubmed: 20037143
J Cell Physiol. 2006 Jul;208(1):64-76
pubmed: 16557516
Circulation. 2010 Dec 7;122(23):2419-29
pubmed: 21098445
Catheter Cardiovasc Interv. 2014 Jan 1;83(1):E17-25
pubmed: 22972685
Can J Vet Res. 2016 Oct;80(4):294-301
pubmed: 27733784
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
Br Med Bull. 2017 Jan 1;121(1):135-154
pubmed: 28164211
Stem Cells. 2006 Feb;24(2):376-85
pubmed: 16322640
J Am Coll Cardiol. 2017 Feb 7;69(5):526-537
pubmed: 27856208
Circ Res. 2013 Jul 5;113(2):153-66
pubmed: 23658436
PLoS One. 2019 Sep 3;14(9):e0221457
pubmed: 31479463
J Cardiovasc Magn Reson. 2016 Sep 30;18(1):63
pubmed: 27688028
Int J Cardiol. 2010 Sep 24;144(1):26-35
pubmed: 19443059
Stem Cells Transl Med. 2017 Nov;6(11):1963-1971
pubmed: 28880460
Neuroscience. 2005;130(4):813-31
pubmed: 15652981
Exp Biol Med (Maywood). 2014 Jan;239(1):105-15
pubmed: 24227633
Stem Cell Res Ther. 2017 Jun 5;8(1):124
pubmed: 28583198
Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7
pubmed: 22771324
PLoS One. 2017 Apr 27;12(4):e0176412
pubmed: 28448588
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
J Am Coll Cardiol. 2012 Jan 31;59(5):539-40
pubmed: 22281257
Dev Dyn. 2001 Oct;222(2):218-27
pubmed: 11668599
J Cardiovasc Transl Res. 2014 Oct;7(7):651-63
pubmed: 25205213
Circ Res. 2008 Jul 3;103(1):107-16
pubmed: 18556576
Cytotherapy. 2013 Aug;15(8):979-85
pubmed: 23725689
PLoS One. 2016 Feb 11;11(2):e0149001
pubmed: 26866919
Eur Heart J. 2001 Dec;22(23):2171-9
pubmed: 11913479
J Tissue Eng Regen Med. 2018 Jan;12(1):e261-e274
pubmed: 28084666
Circ Res. 2014 Apr 11;114(8):1292-301
pubmed: 24449819
JAMA. 2012 Dec 12;308(22):2369-79
pubmed: 23117550
Radiology. 2001 Jan;218(1):215-23
pubmed: 11152805
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2104-2118
pubmed: 28750144
J Int Med Res. 2018 Mar;46(3):951-964
pubmed: 28984178
Circulation. 2009 Sep 22;120(12):1075-83, 7 p following 1083
pubmed: 19738142
Circ Res. 2008 Nov 21;103(11):1204-19
pubmed: 19028920
Cell Death Discov. 2019 Mar 19;5:79
pubmed: 30911413
Curr Stem Cell Res Ther. 2009 Jan;4(1):23-33
pubmed: 19149627
J Cardiovasc Magn Reson. 2006;8(3):417-26
pubmed: 16755827
Circ Res. 2013 Aug 30;113(6):810-34
pubmed: 23989721
J Stem Cell Res Ther. 2015;5(6):1-8
pubmed: 26937295
Am J Physiol Regul Integr Comp Physiol. 2014 Oct 1;307(7):R879-87
pubmed: 25100076
PLoS One. 2016 Jan 19;11(1):e0144523
pubmed: 26784932
Biol Cell. 2011 Apr;103(4):197-208
pubmed: 21332447
J Am Coll Cardiol. 2017 Nov 14;70(20):2504-2515
pubmed: 29145950
N Engl J Med. 2017 May 25;376(21):2053-2064
pubmed: 28538121
Int J Obes (Lond). 2011 Sep;35(9):1141-53
pubmed: 21266947
Cancer Res. 2009 Jul 1;69(13):5331-9
pubmed: 19509230
Europace. 2007 Dec;9(12):1218-21
pubmed: 17951268
Circ Res. 2017 Mar 31;120(7):1139-1150
pubmed: 28031416
Stem Cell Res. 2011 Nov;7(3):219-29
pubmed: 21907165
Sci Rep. 2016 Jan 11;6:19155
pubmed: 26750752
Cell Regen (Lond). 2015 Sep 30;4:7
pubmed: 26435835
PLoS One. 2013;8(3):e59020
pubmed: 23527076
Nat Commun. 2018 Apr 25;9(1):1659
pubmed: 29695718
FEBS Lett. 2007 Aug 21;581(21):3961-6
pubmed: 17662720
J Histochem Cytochem. 2010 Aug;58(8):721-30
pubmed: 20421592
Stem Cell Res Ther. 2016 Jul 16;7(1):94
pubmed: 27423905
J Cardiovasc Magn Reson. 2003;5(4):553-61
pubmed: 14664133
World J Stem Cells. 2019 Feb 26;11(2):124-146
pubmed: 30842809